Vancomycin Prevents Polytetrafluoroethylene Graft Infections in Pediatric Patients Receiving Chronic Hemodialysis
American Journal of Kidney Diseases
Hemodialysis; PTFE grafts; vancomycin
Polytetrafluoroethylene (PTFE) grafts have been a useful addition to the pediatric hemodialysis vascular access armamentarium. In this study, 17 pediatric patients underwent 331 total months of hemodialysis via PTFE grafts. There was a statistically significant (P < .025) decrease in the incidence of graft infections in 12 patients (235 patient-months) while receiving prophylactic parenteral vancomycin compared with 9 patients (96 patient-months) while receiving no vancomycin (0% v 44%). Vancomycin side effects were uncommon and mild. Vancomycin is a safe and effective agent for the prevention of PTFE graft infections in pediatric patients receiving chronic hemodialysis. © 1985, National Kidney Foundation Inc.. All rights reserved.
Fivush, B., Bock, G., Guzzetta, P., Salcedo, J., & Ruley, E. (1985). Vancomycin Prevents Polytetrafluoroethylene Graft Infections in Pediatric Patients Receiving Chronic Hemodialysis. American Journal of Kidney Diseases, 5 (2). http://dx.doi.org/10.1016/S0272-6386(85)80007-X